Commenting on the trial update, Tim McCarthy, Chairman of ImmuPharma LON:IMM said: “We are pleased to give DireectorsTalk a further update of our pivotal Phase III study of Lupuzor(TM) in
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company confirmed that today the Annual Report and Accounts for the year ended 31 December 2016 has today been posted to
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today provided its final results for the twelve months ended 31 December 2016 (the “Period”). Key Highlights (including post Period
ImmuPharma’s Tim McCarthy discusses the latest update on their Phase III Lupuzor study in this exclusive interview with DirectorsTalk
Immupharma Plc (LON:IMM) Chairman, Tim McCarthy talks to DirectorsTalk about its Lupuzor market update. Tim explains the main points to the update, the importance of reaching a milestone where all
Tim McCarthy, Chairman of ImmuPharma PLC (LON:IMM) tells Proactive Investors they’re on schedule to publish first results from their phase III trial of lupus drug Lupuzor early next year with
Commenting on the trial update, Tim McCarthy, Chairman of ImmuPharma plc LON:IMM said: “We are delighted to provide a further update of our pivotal Phase III study of Lupuzor(TM) in
The Lupus Knows No Boundaries e-Report brings together firsthand experiences of people with lupus, their advocates and those who treat them, to tell the real story of lupus, highlighting the
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc (“L&G”) confirming its holding in ImmuPharma of 4,446,545
Tim McCarthy, Chairman of ImmuPharma PLC (LON:IMM) talks to Proactive Investors about the company’s £4.1 million raise from investors after an oversubscribed placing. The new cash infusion is to
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
